期刊文献+

超声造影在肝癌残存病灶微波消融治疗中的应用 被引量:8

原文传递
导出
摘要 目的:探讨超声造影(CEUS)在较大肝癌冷循环微波凝固治疗(PMCT)后残存病灶再次行PMCT治疗中的应用价值。方法:总结我院2008年6月至2013年8月165例肝癌患者经PMCT治疗后,残存病灶不同方式引导进行PMCT的病例资料。结果:本组病灶经CEUS后超声引导下行PMCT治疗后,残存病灶<3 cm及残存病灶≥3 cm的肝癌完全消融率分别达到100%(68/68)、81.63%(40/49),总消融率92.31%(108/117);复习增强CT/MRI后在灰阶超声引导下行PMCT治疗后残存病灶<3 cm及残存病灶≥3 cm的肝癌完全消融率分别达到100%(33/33)、60.87%(28/46),总消融率77.22%(61/79)。<3 cm残存病灶两组完全消融率均100%,差异无统计学意义;≥3 cm残存病灶两组完全消融率及两组总消融率差异有统计学意义(χ2=6.91,P=0.009;χ2=9.04,P=0.003)。所有病例消融术后无胆漏、感染、死亡等严重并发症发生。采用肝脏CEUS判断肿瘤残留,准确性为96.9%,与增强CT/MRI评估相当(P>0.05)。结论:肝脏CEUS能够精准指导肝癌残存病灶行PMCT,并可用于消融术后疗效评价和随访。
出处 《现代医学》 2014年第4期395-397,共3页 Modern Medical Journal
  • 相关文献

参考文献5

  • 1NISHIMURA M, NOUSO K, KARIYAMA K, et al. Safety and efficacy of radiofrequency ablation with artificial ascites for hepatoeellular carcinoma [ J ]. Acta Med Okayama, 2012,66 (3) :279-284.
  • 2SOLBIATI L, IERACE T, TONOLINI M, et al. Guidance and monitoring of radiofrequency liver tumor ablation with contrast- enhanced ultrasound [ J ]. Eur J Radiol, 2004,51 (Suppl) : S19- 23.
  • 3QUAIA E, BERTOLOTFO M, FORGACS B, et al. Detection of liver metastases by pulse inversion harmonic imaging during levovist late phase: comparison with conventional ultrasound and helical CT in 160 patients [ J ]. Eur Radio1,2003,13 (3) : 475-483.
  • 4LU M D, YU X L, LI A H. et al. Comparison of contrast en- hanced ultrasound and contrast enhanced CT or MRI in moni- toring percutaneous thermal ablation procedure in patients with hepatoeellular carcinoma : a multi- center study in China [ J ]. Ultrasound Med Bio1,2007,33 ( 11 ) : 1736-1749.
  • 5秦建民,顾新刚,张敏,吴旸,夏寅娟,王康,殷佩浩,李琦,陈腾.肝脏实时超声造影在肝癌微波消融治疗中的应用[J].肝胆胰外科杂志,2013,25(1):27-30. 被引量:39

二级参考文献8

  • 1戴莹,陈敏华,严昆.应用超声造影剂声诺维提高肝脏恶性肿瘤检出率[J].中华医学超声杂志(电子版),2004,1(3):121-123. 被引量:38
  • 2吕明德,谢晓燕,徐作峰,刘广健,郑艳玲,梁瑾瑜.常规超声和超声造影对肝脏局灶性病变定性诊断的有用性评估[J].中国超声医学杂志,2005,21(12):924-926. 被引量:40
  • 3Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofre- quency ablation for hepatoeellular carcinoma. An analysis of 1000 cases [J]. Cancer, 2005, 103(6): 1201-1209.
  • 4Solbiati L, Ierace T, Tonolini M, et al. Guidance and monito- tingof radiof requency liver tumor ablmion with contrast- enhanced ultrasound [J]. Eur J Radiol, 2004, 51(Suppl): S19- S23.
  • 5Quaia E, Bertolotto M, Forgacs B, et al. Detection of liver metastases by pulse inversion harmonic imaging during Levovist latephase: comparison with conventional ultrasound and heli- cal CT in 160 patients [J]. Eur Radiol, 2003, 13(3): 475-483.
  • 6Lu MD, Yu XL, Li AH, et al. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI inmonitoring percutaneous thermal ablation procedure inpatients with hepa- tocellular carcinoma: a multicenter study in china [J]. Ultra- sound Med, Biol, 2007, 33(11): 1736-1749.
  • 7Kisaka Y, Hirooka M, Kumagi T, et al. Usefulness of contrast. enhanced uhrasonography with abdominal virtual uhrasono- graphyin assessing therapeutic response in hepatocellular car- cinomatreated with radiofrequency ablation [J]. Liver Int, 2006, 26(10): 1241-1247.
  • 8李敬东,刘健,赵学友,袁顺娴,张宁.实时超声造影在肝癌微创治疗术中的临床应用[J].现代中西医结合杂志,2010,19(9):1044-1045. 被引量:6

共引文献38

同被引文献70

  • 1经翔,丁建民,王彦冬,杜智,王毅军,聂福华.超声引导下微波消融治疗肝脏恶性肿瘤328例并发症分析[J].中华医学超声杂志(电子版),2011,8(11):2307-2313. 被引量:14
  • 2叶永强,马宽生,李锐,李晓武,董家鸿.超声造影监测原发性肝癌射频消融术的疗效[J].中华普通外科杂志,2006,21(9):650-653. 被引量:16
  • 3EL- SERAG H B, RUDOLPH K L. Hepatocellular carcinoma :epidemiology and molecular carcinogenesis [ J ]. Gastroenterol- ogy, 2007,132 ( 7 ) : 2557- 2576.
  • 4TAO C, YANG L X. Improved radiotherapy for primary and secondary liver cancer : stereotactic body radiation therapy [ J ]. Anticancer Res,2012,32 (2) ,649- 655.
  • 5SHARPLESS N E, DEPINHO R A. Telomeres, stem cells, se- nescence and cancer[ J]. J Clin Invest,2004,113 (2) : 160-168.
  • 6de WILDE J, KOOTER J M, OVERMEER R M,et al. hTERT promoter activity and CpG methylation in HPV-induced carci- nogenesis [ J]. BMC Cancer,2010,10:271.
  • 7DANIEL M, PEEK G W, TOLLEFSBOL T O. Regulation of the human catalytic subunit of telomerase (hTERT) [ J ]. Gene, 2012,498 (2) : 135-146.
  • 8PARK H C, SEONG J, HANK H, et al. Dose-response rela- tionship inradiotherapy for hepatocellular[ J ]. Int J Radial On- col Boil Phys,2002,54( 1 ) :150-155.
  • 9NG E K, TSUI N B, LAM N Y, et al. Presence of fiherable and non filterable mRNA in the plasma of cancer patients and healthy individuals [ J ]. Clin Chem, 2003,48 : 1212-1217.
  • 10MIURA N, OSAKI Y, NAGASHIMA M, et al. A novel biomar- ker TERT mRNA is applicable for early detection of hepato- ma[ J]. MC Gastroenterol,2010,10 :46.

引证文献8

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部